Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study
The vaccines used had conferred significant immunity on subjects upon receipt of the first dose. This immunity appears to be greater when using the mRNA vaccine than when using the inactivated vaccine.
Authors
- Jean-Claude Makangara-Cigolo (ORCID: https://orcid.org/0000-0002-1791-2247)
- Jean‐Marie Kayembe Ntumba (ORCID: https://orcid.org/0000-0002-1837-5156)
- Steve Ahuka
- Aliocha Natuhoyila Nkodila (ORCID: https://orcid.org/0000-0002-1403-8451)
- Baudouin Buassa-Bu-Tsumbu
- Ben Bepouka (ORCID: https://orcid.org/0000-0003-3063-4234)
- Jean-Robert Rissassi Makulo
- Jérémie Muwonga (ORCID: https://orcid.org/0000-0002-0800-6146)
- Éric Mafuta (ORCID: https://orcid.org/0000-0001-7986-4618)
- Donatien Mangala
- Georges Lelo Mvumbi
- Eric Kasongo Mukenge
- Guyguy Kamwiziku (ORCID: https://orcid.org/0000-0001-6770-3999)
- Mireille Nganga Nkanga
- Benjamin Longo‐Mbenza (ORCID: https://orcid.org/0000-0002-5164-6296)
- Désire Kulimba Mashinda
- Gustave Ntita Ilunga
- Blaise Matondo-Manzambi Sumbu
- Hippolyte Nani-Tuma Situakibanza
- Mamy Zita Ngole
- Murielle Mashi Longokolo
- Fonce Tshibawu Nkunda
- Christian Nsimba Lengo
Institutions
- University of Kinshasa (CD)
- Université Protestante au Congo (CD)
Publication Details
- Journal
- BMC Infectious Diseases
- Published
- 2025-03-11
- DOI
- https://doi.org/10.1186/s12879-025-10754-4
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00